The effect of Tirofiban on the expression of sCD40L and matrix metalloproteinase-9 in patients with ACS after PCI
10.3760/cma.j.issn.1008-6315.2012.02.025
- VernacularTitle:替罗非班对急性冠状动脉综合征患者经皮冠状动脉成形术后基质金属蛋白酶-9与可溶性CD40配体表达的影响
- Author:
Lifeng ZHANG
;
Mixin SUN
;
Junfang ZHANG
;
Guidong WANG
;
Sumei LIU
- Publication Type:Journal Article
- Keywords:
Tirofiban;
sCD40L;
matrix Metalloproteinase-9;
ELISA;
Acute coronary synarome
- From:
Clinical Medicine of China
2012;28(2):179-181
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of Tirofiban on the expression of matrix metalloproteinase(MMP-9)and sCD40L in patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI)and to explore the potential mechanism of anti-artherosclerosis and stabilize plaque by Tirofiban.Methods Eighty-six patients with ACS were enrolled and were randomly divided into the control group and the Tirofiban group with different time periods after PCI.The expression of MMP-9 and sCD40L were tested by ELISA at 6 h,12 h,24 h,36 h after PCI.Results After application of Tirofiban 6 h,12 h,24 h,36 h,the expression of MMP-9 decreased from(228.25 ±0.015)ug/L to(53.56 ±0.02)μg/L and the expression of sCD40L decreased from(321.12 ±0.02)ng/L to(123.32 ±0.02)ng/L,compared with the control group,the difference was significant(P ＜ 0.05).Conclusions Tirofiban can inhibite the expression of sCD40L and MMP-9,the inhibition of the expression of MMP-9 may be related to the CD40/CD40L pathway.This effect may be one of the mechanism of reducing atherosclerotic plaque inflammation and preventing plaque rupture by Tirofiban.
